- Ayurcann Holdings Corp. (AYUR) has announced plans to launch a normal course issuer bid
- Under the NCIB, Ayurcann may acquire up to 6,085,890 common shares between now and February 28, 2023
- Ayurcann Holdings CEO Igal Sudman sat down with Shoran Devi to discuss the news
- Ayurcann is a post-harvest solution provider with a focus on custom processes and pharma-grade products for Canada’s adult-use and medical cannabis industry
- Ayurcann Holdings Corp. (AYUR) is unchanged on the day, trading at C$0.165 per share at 2:30 pm EST
Ayurcann Holdings Corp. (AYUR) has announced plans to launch a normal course issuer bid.
Ayurcann Holdings CEO Igal Sudman sat down with Shoran Devi to discuss the news.
Under the NCIB, the corporation intends to acquire up to 6,085,890 common shares representing approximately 5 per cent of its issued and outstanding common shares.
On any given day during the NCIB, the corporation may purchase up to 15,000 common shares.
Purchases under the NCIB commence as of March 1, 2022, and will end on February 28, 2023, or when the corporation has purchased the maximum number of shares allowed under the NCIB.
Ayurcann may terminate the NCIB earlier if it feels it is appropriate to do so.
The corporation has appointed Canaccord Genuity Corp. to conduct the NCIB. All common shares acquired will be cancelled.
Ayurcann is a post-harvest solution provider with a focus on custom processes and pharma-grade products for Canada’s adult-use and medical cannabis industries.
Ayurcann Holdings Corp. (AYUR) is unchanged on the day, trading at C$0.165 per share at 2:30 pm EST.
